Intra-Cellular Therapies Inc
NASDAQ:ITCI

Watchlist Manager
Intra-Cellular Therapies Inc Logo
Intra-Cellular Therapies Inc
NASDAQ:ITCI
Watchlist
Price: 88.22 USD -0.31% Market Closed
Market Cap: 9.3B USD
Have any thoughts about
Intra-Cellular Therapies Inc?
Write Note

Wall Street
Price Targets

ITCI Price Targets Summary
Intra-Cellular Therapies Inc

Wall Street analysts forecast ITCI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ITCI is 98.1 USD with a low forecast of 74.74 USD and a high forecast of 136.5 USD.

Lowest
Price Target
74.74 USD
15% Downside
Average
Price Target
98.1 USD
11% Upside
Highest
Price Target
136.5 USD
55% Upside

ITCI Last Price Targets
Intra-Cellular Therapies Inc

The latest public price target was made on Oct 30, 2024 by Corinne Jenkins from Goldman Sachs , who expects ITCI stock to drop by 10% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Corinne Jenkins
Goldman Sachs
79 USD
Downside 10%
2 weeks ago
Oct 30, 2024
Intra-Cellular Therapies (ITCI) PT Raised to $79 at Goldman Sachs
StreetInsider
David Amsellem
Piper Sandler
92 USD
Upside 4%
2 months ago
Sep 5, 2024
Intra-Cellular upgraded to Overweight from Neutral at Piper Sandler
TheFly
Brian Abrahams
RBC Capital
106 USD
Upside 20%
3 months ago
Aug 8, 2024
Intra-Cellular Therapies (ITCI) PT Lowered to $106 at RBC Capital
StreetInsider
Corinne Jenkins
Goldman Sachs
74 USD
Downside 16%
3 months ago
Aug 7, 2024
Intra-Cellular price target lowered to $74 from $77 at Goldman Sachs
TheFly
Ami Fadia
Needham
100 USD
Upside 13%
3 months ago
Jul 22, 2024
Intra-Cellular Therapies (ITCI) PT Raised to $100 at Needham
StreetInsider
Ashwani Verma
UBS
83 USD
Downside 6%
4 months ago
Jun 25, 2024
UBS Downgrades Intra-Cellular Therapies (ITCI) to Neutral (earlier)
StreetInsider
Graig Suvannavejh
Mizuho Securities
100 USD
Upside 13%
4 months ago
Jun 20, 2024
Intra-Cellular Therapies (ITCI) PT Raised to $100 at Mizuho, 'Top Pick'
StreetInsider
Brian Abrahams
RBC Capital
103 USD
Upside 17%
4 months ago
Jun 18, 2024
Intra-Cellular Therapies (ITCI) PT Raised to $103 at RBC Capital
StreetInsider
Andrew Tsai
Jefferies
105 USD
Upside 19%
6 months ago
May 7, 2024
Jefferies Positive on Intra-Cellular Therapies (ITCI): 'We like the setup ahead of the second MDD readout in late-Q2'
StreetInsider
Brian Abrahams
RBC Capital
96 USD
Upside 9%
6 months ago
May 7, 2024
Intra-Cellular Therapies (ITCI) PT Lowered to $96 at RBC Capital
StreetInsider
Sumant Kulkarni
Canaccord Genuity
107 USD
Upside 21%
6 months ago
Apr 23, 2024
Intra-Cellular Therapies (ITCI) PT Raised to $107 at Canaccord Genuity
StreetInsider
Joel Beatty
Robert W. Baird
103 USD
Upside 17%
6 months ago
Apr 17, 2024
Intra-Cellular Therapies (ITCI) PT Raised to $103 at Baird
StreetInsider
Ami Fadia
Needham
82 USD
Downside 7%
7 months ago
Apr 5, 2024
Needham remains positive on Intra-Cellular ahead of Caplyta readouts
TheFly
Show More Price Targets
Show Less Price Targets
Corinne Jenkins
Goldman Sachs
Price Target 79 USD
Upside/Downside 10%
View Source
David Amsellem
Piper Sandler
Price Target 92 USD
Upside/Downside 4%
View Source
Brian Abrahams
RBC Capital
Price Target 106 USD
Upside/Downside 20%
View Source
Corinne Jenkins
Goldman Sachs
Price Target 74 USD
Upside/Downside 16%
View Source
Ami Fadia
Needham
Price Target 100 USD
Upside/Downside 13%
View Source
Ashwani Verma
UBS
Price Target 83 USD
Upside/Downside 6%
View Source
Graig Suvannavejh
Mizuho Securities
Price Target 100 USD
Upside/Downside 13%
View Source
Brian Abrahams
RBC Capital
Price Target 103 USD
Upside/Downside 17%
View Source
Andrew Tsai
Jefferies
Price Target 105 USD
Upside/Downside 19%
View Source
Brian Abrahams
RBC Capital
Price Target 96 USD
Upside/Downside 9%
View Source
Sumant Kulkarni
Canaccord Genuity
Price Target 107 USD
Upside/Downside 21%
View Source
Joel Beatty
Robert W. Baird
Price Target 103 USD
Upside/Downside 17%
View Source
Ami Fadia
Needham
Price Target 82 USD
Upside/Downside 7%
View Source
Show More Price Targets
Show Less Price Targets
Intra-Cellular Therapies Inc Competitors:
Price Targets
4016
Middle East Pharmaceutical Industries Company SJSC
10% Upside
FAE
Faes Farma SA
14% Upside
1666
Tong Ren Tang Technologies Co Ltd
26% Upside
CTLT
Catalent Inc
5% Upside
GLAND
Gland Pharma Ltd
8% Upside
PAHC
Phibro Animal Health Corp
32% Downside
RHONEMA
Rhone Ma Holdings Bhd
4% Upside
EMCURE
Emcure Pharmaceuticals Ltd
20% Upside

Revenue
Forecast

Revenue Estimate
Intra-Cellular Therapies Inc

For the last 8 years the compound annual growth rate for Intra-Cellular Therapies Inc's revenue is 187%. The projected CAGR for the next 3 years is 45%.

187%
Past Growth
45%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Intra-Cellular Therapies Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Intra-Cellular Therapies Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ITCI's stock price target?
Price Target
98.1 USD

According to Wall Street analysts, the average 1-year price target for ITCI is 98.1 USD with a low forecast of 74.74 USD and a high forecast of 136.5 USD.

What is Intra-Cellular Therapies Inc's Revenue forecast?
Projected CAGR
45%

For the last 8 years the compound annual growth rate for Intra-Cellular Therapies Inc's revenue is 187%. The projected CAGR for the next 3 years is 45%.

Back to Top